Vimarsana
Biggest News Aggregation in the World

Bayer Cross News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bayer Cross. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bayer Cross Today - Breaking & Trending Today

Leverkusen's unbeaten season puts the spotlight on an often-overlooked German city - Vimarsana News

Leverkusen's unbeaten season puts the spotlight on an often-overlooked German city

An often-overlooked, small German city dominated by the pharmaceuticals industry is making an unlikely case to be considered one of Europe's soccer capitals this season because of Bayer Leverkusen’s historic unbeaten streak. Coached by former Champions League and World Cup winner Xabi Alonso, the team finished an entire German Bundesliga season without a single loss, the first ever to do so. The team can finish the season with three trophies if it beats Atalanta in the Europa League final Wednesday and Kaiserslautern in the German Cup final three days later.

Source: yahoo.com
Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination - Vimarsana News

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

WHIPPANY, N.J.--(BUSINESS WIRE)--Nov 17, 2023--

Bayer Provides Update on Aliqopa® (copanlisib) - Vimarsana News

Bayer Provides Update on Aliqopa® (copanlisib)

WHIPPANY, N.J.--(BUSINESS WIRE)--Nov 13, 2023--

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study - Vimarsana News

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study

MELBOURNE, Australia, May 8, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has...

Telix to Supply Bayer with Illuccix for Global Phase III Prostate Cancer Study - Vimarsana News

Telix to Supply Bayer with Illuccix for Global Phase III Prostate Cancer Study

MELBOURNE, Australia, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injection)[1] for the Phase III ARASTEP study (ClinicalTrials.gov Identifier: NCT05794906). This global study is investigating the efficacy of Bayer's androgen receptor inhibitor (ARi) darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk bioch...